ARGX
argenx SECOperating peers and competitors
Source-backed product markets and frozen research comparisons. Valuation comparators remain in the existing peer table.
Loading market evidence...
Research comparisons do not establish forecast usefulness or trading returns.
Compare shared product markets
Membership only; no portfolio weights or estimated losses.
Peer overview
Direct development-stage FcRn comparator: Immunovant is testing IMVT-1402 in potentially registrational myasthenia gravis and CIDP studies, overlapping VYVGART's core diseases. Its Sjögren's study also makes the UNITY setback relevant to class sentiment, but ARGX's marketed franchise and IMVT's pre-commercial profile make valuation multiples non-comparable. [Immunovant update](https://www.immunovant.com/investors/news-events/press-releases/detail/83/immunovant-provides-corporate-updates-and-reports-financial)
Grade position vs IMVT
Rotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.

